GlassScriptPhysician profile
Francois Gregoire
NPI 1740462704
$4,190.87
in general payments reported to CMS, 2019-2025
28 companies · $16.16 in 2025
The $16.16 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $911 · 2020: $617 · 2021: $562 · 2022: $826 · 2023: $6.34 · 2024: $1,252 · 2025: $16.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,235 · Food and Beverage: $39.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,235.36 |
| Food and Beverage | $39.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,867.18 | 2022-2024 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $742.93 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.37 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $320.65 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $129.40 | 2019-2022 | |
| Mylan Specialty L.P. | $118.70 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $92.61 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.35 | 2021 | |
| Sunovion Pharmaceuticals INC. | $78.41 | 2019 | |
| Genzyme Corporation | $56.75 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $55.90 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $32.08 | 2021 | |
| Harmony Biosciences LLC | $23.93 | 2021 | |
| Genentech USA, INC. | $23.02 | 2019 | |
| Alexion Pharmaceuticals, INC. | $21.49 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $18.92 | 2019 | |
| Ethicon INC. | $18.01 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.68 | 2020 | |
| Amgen INC. | $16.16 | 2025 | Tezspire |
| Philips North America LLC | $15.84 | 2021 | |
| Paratek Pharmaceuticals, INC. | $15.68 | 2021 | |
| Grifols USA, LLC | $15.05 | 2021 | |
| Insmed, INC. | $14.72 | 2020 | |
| Resmed Corp | $14.56 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.47 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $14.38 | 2019 | |
| Shire North American Group INC | $13.98 | 2019 | |
| Advanced Respiratory, INC | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francois Gregoire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.